NRIX

Nurix Therapeutics Inc

Add to Watchlist

Advanced Chart

9.560

+0.100(+1.060%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

9.690

Open

9.460

VWAP

9.61

Vol

437.89K

Mkt Cap

728.81M

Low

9.330

Amount

4.21M

EV/EBITDA(TTM)

Total Shares

61.07M

171.51M

EV/OCF(TTM)

P/S(TTM)

12.45

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

13.52M

+1.79%

-0.842

+12.24%

14.53M

+15.41%

-0.804

+20.06%

16.36M

+35.26%

-0.761

+7.19%

Estimates Revision

The market is revising Upward the revenue expectations for Nurix Therapeutics, Inc. (NRIX) for FY2025, with the revenue forecasts being adjusted by 12.7% over the past three months. During the same period, the stock price has changed by -42.86%.

Revenue Estimates for FY2025

Revise Upward

+12.7%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.55%

In Past 3 Month

Stock Price

Go Down

-42.86%

In Past 3 Month

14 Analyst Rating

208.58% Upside

Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 29.50 USD with a low forecast of 16.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

2 Hold

0 Sell

Strong Buy

208.58% Upside

Current: 9.560

Low

16.00

Averages

29.50

High

36.00

208.58% Upside

Current: 9.560

Low

16.00

Averages

29.50

High

36.00

Needham

Gil Blum

Strong Buy

Reiterates

$27

2025-04-29

Reason

Needham

Gil Blum

Price Target

$27

2025-04-29

Reiterates

Strong Buy

Reason

Needham

Gil Blum

Strong Buy

Maintains

$28 → $27

2025-04-09

Reason

Needham

Gil Blum

Price Target

$28 → $27

2025-04-09

Maintains

Strong Buy

Reason

Stifel

Stephen Willey

Strong Buy

Maintains

$36 → $35

2025-04-09

Reason

Stifel

Stephen Willey

Price Target

$36 → $35

2025-04-09

Maintains

Strong Buy

Reason

Stifel lowered the firm's price target on Nurix Therapeutics to $35 from $36 and keeps a Buy rating on the shares. The firm continues to view Nurix as "a high-quality company" featuring a lead asset, bexobrutideg, with "a clear path to registration in an established multi-billion-dollar CLL market." The disclosure of incremental bexobrutideg data updates and registrational trial design plans should improve visibility into this path forward, the analyst tells investors.

Wells Fargo

Derek Archila

Buy

Maintains

$32 → $25

2025-04-09

Reason

Wells Fargo

Derek Archila

Price Target

$32 → $25

2025-04-09

Maintains

Buy

Reason

Wells Fargo analyst Derek Archila lowered the firm's price target on Nurix Therapeutics to $25 from $32 and keeps an Overweight rating on the shares. The firm views bexobrutideg as highly de-risked in CLL and thinks regulatory updates and initiation of pivotal trials are modest catalysts in 2025. With shares approaching 52-week lows, it offers an attractive entry point for long-term investors, Wells adds.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$36

2025-04-02

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$36

2025-04-02

Reiterates

Strong Buy

Reason

Leerink Partners

Faisal Khurshid

Hold

Initiates

$16

2025-03-17

Reason

Leerink Partners

Faisal Khurshid

Price Target

$16

2025-03-17

Initiates

Hold

Reason

Leerink analyst Faisal A. Khurshid initiated coverage of Nurix Therapeutics with a Market Perform rating and $16 price target. The firm notes the company is developing early-stage protein degraders in oncology and I&I. While the early data for BTK degrader NX-5948 in CLL are compelling, Leerink has reservations on the path to value creation without a strategic partner. The firm is optimistic on the prospects in I&I for NX-5948 and partnered programs, but these programs are in highly competitive spaces, and Leerink would need to see further progress to have higher conviction.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Nurix Therapeutics Inc (NRIX.O) is -3.16, compared to its 5-year average forward P/E of -6.91. For a more detailed relative valuation and DCF analysis to assess Nurix Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.91

Current PE

-3.16

Overvalued PE

-2.53

Undervalued PE

-11.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.65

Current EV/EBITDA

-0.90

Overvalued EV/EBITDA

-0.21

Undervalued EV/EBITDA

-9.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

19.95

Current PS

11.93

Overvalued PS

32.89

Undervalued PS

7.00

Financials

Annual

Quarterly

FY2025Q1

YoY :

+11.26%

18.45M

Total Revenue

FY2025Q1

YoY :

+39.02%

-62.86M

Operating Profit

FY2025Q1

YoY :

+35.73%

-56.35M

Net Income after Tax

FY2025Q1

YoY :

-11.84%

-0.67

EPS - Diluted

FY2025Q1

YoY :

+44.02%

-64.57M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+244.61%

-357.33

FCF Margin - %

FY2025Q1

YoY :

+21.99%

-305.38

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

254.8K

USD

3-6

Months

545.4K

USD

6-9

Months

986.9K

USD

0-12

Months

1.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 749.22% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.0M

Volume

6-9

Months

0.0

Volume

0-12

Months

118.8K

Volume

Bought

0-3

0.0

Volume

Months

3-6

4.9M

Volume

Months

6-9

0.0

Volume

Months

0-12

7.6M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

254.8K

USD

3-6

Months

545.4K

USD

6-9

Months

986.9K

USD

0-12

Months

1.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

NRIX News & Events

Events Timeline

2025-05-06 (ET)

2025-05-06

14:14:54

Oncology stocks 'bearing the brunt' of Prasad news, says Oppenheimer

2025-04-17 (ET)

2025-04-17

07:03:07

Nurix Therapeutics announces FDA cleared the IND for GS-6791/NX-0479

2025-04-08 (ET)

2025-04-08

16:02:40

Nurix Therapeutics reports Q1 EPS (67c), consensus (76c)

News

1.0

05-15Newsfilter

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

4.0

04-29Benzinga

Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views

4.0

04-29Benzinga

Needham Reiterates Buy on Nurix Therapeutics, Maintains $27 Price Target

People Also Watch

Oxford Industries Inc

US Physical Therapy Inc

Kiniksa Pharmaceuticals Ltd

AMC Entertainment Holdings Inc

FAQ

What is Nurix Therapeutics Inc (NRIX) stock price today?

The current price of NRIX is 9.56 USD — it has increased 1.06 % in the last trading day.

NRIX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

NRIX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Nurix Therapeutics Inc (NRIX) stock price today?

What is Nurix Therapeutics Inc (NRIX)'s business?

What is the price predicton of NRIX Stock?

What is Nurix Therapeutics Inc (NRIX)'s revenue for the last quarter?

What is Nurix Therapeutics Inc (NRIX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Nurix Therapeutics Inc (NRIX)'s fundamentals?

How many employees does Nurix Therapeutics Inc (NRIX). have?

What is Nurix Therapeutics Inc (NRIX) market cap?